An imageable retinoid acid derivative to detect human cancer xenografts and study therapeutic dosing to reduce its toxicity

LAUR Repository

Show simple item record

dc.contributor.author Wang, Wei
dc.contributor.author Qiu, Xiuchun
dc.contributor.author Zhang, Fujun
dc.contributor.author Sun, Jin
dc.contributor.author Cameron, Arlin G.
dc.contributor.author Wendt, Juliet A.
dc.contributor.author Mawad, Michel E.
dc.contributor.author Ke, Shi
dc.date.accessioned 2019-07-10T05:52:12Z
dc.date.available 2019-07-10T05:52:12Z
dc.date.copyright 2010 en_US
dc.date.issued 2019-07-10
dc.identifier.issn 1555-4317 en_US
dc.identifier.uri http://hdl.handle.net/10725/11021
dc.description.abstract Developing agents with ‘seek, treat and see’ capability is critical for personalized molecular medicine. Those agents will specifically target the disease markers for diagnosis and apply the biologically effective dose for treatment. Retinoids regulate a multitude of biological processes. In addition, retinoic acid can reverse premalignancy, significantly decrease second primary tumors and provide a treatment benefit in head and neck, lung, esophagus, colon and bladder cancer. These data suggest that cancer cells can take up retinoids. Therefore, retinoids are potential tumor‐imaging agents. We developed near‐infrared (NIR)‐labeled retinoid agents to detect human cancers, visualize drug redistribution within the body, determine the optimal biological dose and reduce systemic toxicity. Our data demonstrate that the retinoid agent, but not the free dye, binds to the human tumor cells and is internalized, where it permits the imaging of human cancer xenografts. The high dose of retinoid agent is significantly associated with systemic toxicity. In summary, synthetic NIR‐labeled retinoid agents can be used to detect multiple human cancer xenografts as the agent is internalized by cancer cells. The binding of the agent to the tumor xenografts is dependent on the redistribution of the agent. Therapeutic agents labeled with reporters will interrogate tumor–drug interactions and permit analysis of biodistribution, pharmacokinetics and pharmacodynamics in real time. At the same time, we can apply the biologically effective dose for therapy, instead of the traditional maximum tolerated dose, to reduce systemic toxicity en_US
dc.language.iso en en_US
dc.title An imageable retinoid acid derivative to detect human cancer xenografts and study therapeutic dosing to reduce its toxicity en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 201700518 en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Contrast Media & Molecular Imaging en_US
dc.journal.volume 6 en_US
dc.journal.issue 4 en_US
dc.article.pages 200-208 en_US
dc.keywords Molecular imaging en_US
dc.keywords Multimodality imaging en_US
dc.keywords Cellular uptake en_US
dc.keywords Optical imaging en_US
dc.keywords Cancer en_US
dc.keywords Near‐infrared en_US
dc.identifier.doi https://doi.org/10.1002/cmmi.419 en_US
dc.identifier.ctation Wang, W., Qiu, X., Zhang, F., Sun, J., Cameron, A. G., Wendt, J. A., ... & Ke, S. (2011). An imageable retinoid acid derivative to detect human cancer xenografts and study therapeutic dosing to reduce its toxicity. Contrast media & molecular imaging, 6(4), 200-208. en_US
dc.author.email michel.mawad@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://onlinelibrary.wiley.com/doi/full/10.1002/cmmi.419 en_US
dc.author.affiliation Lebanese American University en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account